Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.68 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL28262258 | 0.92 | CYP17A1 (0.60) | CYP17A1NAMPTMDM2BCHEPSMB8 | |
| SCHEMBL4759920 | 0.90 | CYP17A1 (0.79) | CYP17A1NAMPTPSMB8BCL2BECN1 | |
| SCHEMBL21140934 | 0.89 | NAMPT (0.74) | CYP17A1NAMPTPOLBKDM4EL3MBTL1 | |
| SCHEMBL23637726 | 0.87 | CYP17A1 (0.63) | CYP17A1NAMPTPSMB8 | |
| SCHEMBL6815524 | 0.87 | NAMPT (0.71) | CYP17A1NAMPTKDM4EL3MBTL1 | |
| SCHEMBL13055402 | 0.86 | CYP17A1 (0.59) | CYP17A1NAMPTPSMB8L3MBTL1MAP4K4 | |
| SCHEMBL31029060 | 0.86 | CYP17A1 (0.61) | CYP17A1NAMPTBCHEPSMB8POLB | |
| SCHEMBL29260233 | 0.86 | CYP17A1 (0.92) | CYP17A1NAMPTPOLB | |
| SCHEMBL11674360 | 0.83 | CYP17A1 (0.55) | CYP17A1NAMPTMDM2BCHEPOLB | |
| SCHEMBL30125128 | 0.82 | CYP17A1 (1.00) | CYP17A1NAMPTPSMB8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496624-A | Resin composition and use thereof | 华为技术有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20230058178-A1 | METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING | UNITED STATES GOVERNMENT | 2023-02-23 | — | — | US | claimed |
| WO-2021150773-A1 | METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-07-29 | — | — | WO | claimed |
| EP-2850044-B1 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | UNIV CHICAGO (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2850044-A2 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | The University of Chicago (US) | 2015-03-25 | — | — | EP | claimed |
| US-20140004044-A1 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | THE UNIVERSITY OF CHICAGO (US) | 2014-01-02 | — | — | US | claimed |
| WO-2013173746-A2 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | THE UNIVERSITY OF CHICAGO (US) | 2013-11-21 | — | — | WO | claimed |
| CN-101723911-B | Method for synthesizing N-aryl-1,3-oxazolin-2-one compounds | UNIV XUZHOU NORMAL | 2012-07-04 | — | — | CN | claimed |
| CN-101723911-A | Method for synthesizing N-aryl-1,3-oxazolin-2-one compounds | UNIV XUZHOU NORMAL | 2010-06-09 | — | — | CN | claimed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | claimed |
| CN-1745064-A | Pyridines for the treatment of damaged mammalian neural tissue | PURDUE RESEARCH FOUNDATION (US) | 2006-03-08 | — | — | CN | claimed |
| US-20040171587-A1 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION | 2004-09-02 | — | — | US | claimed |
| US-20250270200-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2025-08-28 | — | — | US | disclosed |
| US-12281116-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025057074-A1 | N-ARYL BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| EP-4511035-A1 | CTPS1 INHIBITORS AND USES THEREOF | Nimbus Clotho, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| US-4690921-A | BACTERICIDES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-09-01 | — | — | US | disclosed |
| EP-0142274-A2 | Cephalosporin compounds and salts thereof, their production, and medicaments containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281116-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | CYP17A1 4412/4885NAMPT 1345/4885MDM2 1726/4885 |
| US-20040171587-A1 | Pyridines for treating injured mammalian nerve tissue | P2RY4, INA, P2RY1 | CYP17A1 4825/4885NAMPT 610/4885MDM2 3959/4885 |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | CYP17A1 4823/4885NAMPT 616/4885MDM2 3943/4885 |
| US-20250270200-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | CYP17A1 920/4885NAMPT 171/4885MDM2 2718/4885 |
| US-20140004044-A1 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | KCNJ4, KCNQ4, KCND2 | CYP17A1 4885/4885NAMPT 3665/4885MDM2 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.